文献速递外周动脉疾病

BEST-CLI 试验入组障碍调查:高绩效与低绩效中心的比较

Enrollment Obstacles in a Randomized Controlled Trial: A Performance Survey of Enrollment in BEST-CLI Sites.
PubMed 文献 · Ann Vasc Surg · 2019-09-03

该研究通过问卷调查比较 BEST-CLI 试验中 30 个高绩效中心与 30 个低绩效中心的入组障碍。高绩效中心最常见障碍是难以说服患者及家属参与(36%),低绩效中心则为难以说服患者和难以激励研究者(各 29%)。患者认知与研究者的偏好是大型随机对照试验入组的主要挑战。

要点

  • 高绩效中心入组障碍主要是说服患者及家属困难(36%)。
  • 低绩效中心入组障碍为说服患者和激励研究者困难(各29%)。
  • 患者/家属对血运重建策略有强烈偏好是同意试验的主要障碍。

核心结论

  • 患者认知和研究者的偏好是大型随机对照试验入组的显著挑战。
  • 在 BEST-CLI 试验中,难以说服患者及家属接受随机分组和难以激励研究者是主要入组障碍。

研究设计与样本

  • BEST-CLI 是一项前瞻性、实用性、多中心、多学科随机对照试验,计划在北美、欧洲和新西兰的 160 个中心入组 2100 例严重肢体缺血患者。
  • 调查了 30 个高绩效中心和 30 个低绩效中心,高绩效定义为每月入组至少 0.5 例或总入组超过 8 例,低绩效定义为每月入组 0.1 例或仅入组 1 例。
  • 高绩效中心有 22/30(73%)回复调查,低绩效中心有 14/30(47%)回复(P = 0.06),包括 17 名研究者和 31 名协调员。

主要发现

  • 高绩效中心和低绩效中心的平均总入组量分别为 12.5 例和 1.0 例,入组速率分别为每月 1.5 例和每月 0.1 例。
  • 高绩效中心最常见的入组障碍是难以说服患者及家属参与(36%),低绩效中心则为难以说服患者和难以激励研究者(各 29%)。
  • 高绩效中心同意患者参加试验的最常见障碍是患者/家属对血运重建策略有强烈偏好(32%),低绩效中心则为患者/家属不希望治疗被随机选择(36%)。
  • 55% 的高绩效中心和 43% 的低绩效中心报告试验团队极其合作(P = 0.73),68% 的高绩效中心和 64% 的低绩效中心报告已确定团队中的试验倡导者(P = 1)。
  • 高绩效中心认为最严格的入组标准是既往同侧肢体支架植入伴显著再狭窄(32%),低绩效中心则认为外科旁路手术风险过高(43%)。

关键数值与推荐

  • 高绩效中心定义:每月入组至少 0.5 例或总入组超过 8 例;低绩效中心定义:每月入组 0.1 例或仅入组 1 例。
  • 入组辅助材料的使用在高绩效中心和低绩效中心相似:患者手册使用率分别为 59% 和 64%(P = 1),研究者谈话要点使用率分别为 45% 和 36%(P = 0.73)。

临床怎么用

  • 识别并针对患者及家属的偏好进行沟通可能改善随机对照试验的入组。
  • 激励研究者和确定试验倡导者可能是提高低绩效中心入组率的策略。

局限性

  • 调查回复率在高绩效中心和低绩效中心分别为 73% 和 47%,存在无应答偏倚可能。
  • 样本仅来自 BEST-CLI 试验的中心,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although randomized controlled trials (RCTs) provide the most reliable form of scientific evidence, they are challenging to complete because of a variety of enrollment obstacles. We evaluated obstacles in a large RCT by comparing survey results at high-performing sites (HPS) and low-performing sites (LPS). METHODS: The Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI) trial is a prospective, pragmatic, multicenter, and multispecialty RCT that will compare clinical outcomes, quality of life, and cost in patients with CLI randomized to surgical bypass or endovascular therapy. BEST-CLI aims to enroll 2100 patients at 160 sites in North America, Europe, and New Zealand. We surveyed the 30 HPS and 30 LPS to assess perceptions of enrollment obstacles. HPS were defined by enrollment of 0.5 subjects or more per month or more than 8 total subjects enrolled. LPS were defined by enrollment of 0.1 subjects per month or only 1 subject total. Responses were compared by site performance status. RESULTS: There were 22 of 30 (73%) HPS and 14 of 30 (47%) LPS that answered the survey (P = 0.06), including 17 investigators and 31 coordinators. The mean total enrollment and rate of enrollment at HPS and LPS were 12.5 subjects at 1.5 subjects/month and 1.0 subject at 0.1 subjects/month, respectively. The most common barrier to enrollment at HPS was difficulty convincing patients and their families to participate (36%), whereas at LPS both difficulty convincing patients and difficulty motivating investigators to enroll (29% each) were most frequently cited. At HPS, the most common obstacle to consenting patients for the trial was patient/family having strong preference toward revascularization strategy (32%) and at LPS it was patient/family not wanting to have treatment chosen at random (36%). At 55% of HPS and 43% of LPS, the trial team was reported as extremely collaborative (P = 0.73), whereas 68% of HPS and 64% of LPS reported having identified a trial champion on their team (P = 1). The most restrictive perceived enrollment criterion at HPS was prior index limb stenting with significant restenosis (32%), whereas at LPS it was excessive risk for surgical bypass (43%). Materials to aid enrollment were used equally at HPS and LPS: patient brochures at 59% HPS and 64% LPS (P = 1); investigator talking points at 45% of HPS and 36% of LPS (P = 0.73). CONCLUSIONS: Patient perceptions and investigator biases are significant challenges to enrollment in large RCTs. In the BEST-CLI trial, difficulty convincing patients and families to allow treatment randomization and difficulty in motivating investigators were major enrollment obstacles.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Villarreal MF, Siracuse JJ, Menard M, et al. Enrollment Obstacles in a Randomized Controlled Trial: A Performance Survey of Enrollment in BEST-CLI Sites. Ann Vasc Surg. 2019. PMID: 31491479. doi:10.1016/j.avsg.2019.08.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。